Hyperpax en es it fr

Hyperpax Brand names, Hyperpax Analogs

Hyperpax Brand Names Mixture

  • No information avaliable

Hyperpax Chemical_Formula


Hyperpax RX_link


Hyperpax fda sheet

Hyperpax FDA

Hyperpax msds (material safety sheet)

Hyperpax MSDS

Hyperpax Synthesis Reference

No information avaliable

Hyperpax Molecular Weight

1270.28 g/mol

Hyperpax Melting Point

No information avaliable

Hyperpax H2O Solubility

Freely soluble as sodium salt (> 200mg/mL)

Hyperpax State


Hyperpax LogP

No information avaliable

Hyperpax Dosage Forms

Powder for solution (for injection)

Hyperpax Indication

For use in the treatment of patients with esophageal candidiasis and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

Hyperpax Pharmacology

Formerly known as FK463, micafungin is a novel antifungal agent. It is a glucan synthesis inhibitor of the echinocandin structural class. The U.S. Food and Drug Administration approved micafungin in March 2005. Micafungin inhibits an enzyme essential for fungal cell-wall synthesis and is fungicidal (lethal) for Candida. Micafungin can be used concomitantly with a variety of other drugs, including the HIV protease inhibitor ritonavir and the transplant medications cyclosporine and tacrolimus.

Hyperpax Absorption

No information avaliable

Hyperpax side effects and Toxicity

Intravenous LD50 in rats is 125mg/kg. In dogs it is >200mg/kg. No cases of overdosage have been reported. Repeated daily doses up to 8 mg/kg (maximum total dose of 896 mg) in adult patients have been administered in clinical trials with no reported dose-limiting toxicity. The minimum lethal dose is 125 mg/kg in rats, equivalent to 8.1 times the recommended human clinical dose for esophageal candidiasis based on body surface area comparisons.

Hyperpax Patient Information

No information avaliable

Hyperpax Organisms Affected

Aspergillis, Candida and other fungi